05:02 AM EDT, 06/14/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Friday initial data from each of the first two patients dosed with its CABA-201 experimental therapy to treat autoimmune disease in early-to-mid-stage studies showed the treatment was well-tolerated and potentially effective in resetting the immune system.

The company said the data showed no serious adverse events, cytokine release syndrome or neurotoxicity, adding that both patients experienced complete B cell depletion and clinical improvements.

Cabaletta said it plans to continue expanding its trials to address unmet needs in autoimmune diseases with durable remissions from a single infusion of CABA-201.

Price: 12.65, Change: +0.09, Percent Change: +0.72